Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 10/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7544978 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1CYP19A1TSHR | |
| Hydrochloric Acid SCHEMBL6220254 | 0.98 | GNAO1 (0.38) | GNAO1GNAI3GNAI1CYP19A1 | |
| Bromide SCHEMBL31310728 | 0.96 | GNAO1 (0.37) | GNAO1GNAI3GNAI1CYP19A1TSHR | |
| SCHEMBL30481636 | 0.93 | HSD17B10 (0.34) | GNAO1GNAI3GNAI1GAA | |
| SCHEMBL27483509 | 0.90 | GNAO1 (0.34) | GNAO1GNAI3GNAI1CYP19A1TSHR | |
| SCHEMBL27560213 | 0.90 | GNAO1 (0.34) | GNAO1GNAI3GNAI1CYP19A1TSHR | |
| SCHEMBL27497819 | 0.90 | GNAO1 (0.34) | GNAO1GNAI3GNAI1CYP19A1TSHR | |
| SCHEMBL5805215 | 0.87 | GAA (0.39) | GAA | |
| SCHEMBL27527033 | 0.85 | HSD17B10 (0.31) | — | |
| SCHEMBL14536280 | 0.84 | HSD17B10 (0.32) | GNAO1GNAI3GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | claimed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | claimed |
| US-9029547-B1 | Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal | SAMI LABS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| US-9029547-B1 | Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal | SAMI LABS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| US-9029547-B1 | Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal | SAMI LABS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| US-8853407-B1 | Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal | SAMI LABS LIMITED (IN) | 2014-10-07 | — | — | US | disclosed |
| US-8853407-B1 | Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal | SAMI LABS LIMITED (IN) | 2014-10-07 | — | — | US | disclosed |
| US-8853407-B1 | Synthesis of 4-aryl 4-acyl piperidine, its salts and analogs using indium metal | SAMI LABS LIMITED (IN) | 2014-10-07 | — | — | US | disclosed |
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1998031669-A1 | NOVEL ARYLPIPERAZINE DERIVED FROM PIPERIDINE AS ANTIDEPRESSANT MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 1998-07-23 | — | — | WO | disclosed |
| US-5364867-A | For treatment of psychosis | STERLING WINTHROP INC. (US) | 1994-11-15 | — | — | US | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | GNAO1 622/4885GNAI3 1102/4885GNAI1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.